Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma

Trial Profile

Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Bortezomib (Primary) ; Tanespimycin (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms TIME-2
  • Sponsors Bristol-Myers Squibb; Kosan Biosciences
  • Most Recent Events

    • 05 Dec 2009 Results were presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009)
    • 22 May 2009 Actual initiation date changed from Nov 2008 to Aug 2007 as reported by ClinicalTrials.gov.
    • 06 May 2009 Actual end date (1 Feb 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top